Soligenix published HyBryte versus Valchlor data in CTCL. Read what it changes for approval, adoption, and competitive positioning.
Accent Therapeutics is expanding the ATX-295 story in solid tumors. Read what the new AACR 2026 data could change and what risks remain.
Nuvation Bio now controls safusidenib globally. Read why the Japan deal matters for IDH1-mutant glioma, SIGMA, and the post-vorasidenib market.
Scinai Immunotherapeutics doubled CDMO revenue in 2025. Read what the Recipharm deal and PC111 focus could mean for its biotech strategy.
Abbisko Therapeutics won EMA orphan drug designation for irpagratinib in liver cancer. Read what this changes for FGFR4-targeted therapy.
Tenpoint Therapeutics and PHIL launch YUVEZZI direct-to-patient access for presbyopia. Read what it means for affordability, uptake, and market adoption.
PharmaEssentia’s Puerto Rico facility could reshape BESREMi supply resilience and U.S. expansion. Read what this means for biologics strategy.
CTIS launches Trial SafetyXchange to help pharma firms meet the FDA E2B(R3) deadline. Read what it changes for safety reporting teams.
Aspect Biosystems has secured a $280 million Canada-backed push in regenerative medicine. Read what it means for cellular therapy scale-up.
Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.